伊立替康加顺铂同步放化疗对局部晚期食管癌的疗效观察

目的探讨伊立替康加顺铂同步放化疗对局部晚期食管癌的疗效及不良反应。方法全部病例化疗均采用顺铂30 mg/m2,伊立替康65 mg/m2,第1天及第8天,21天重复,共4个周期。化疗同时行放疗,标准为1.8～2.0Gy/次,每周5次,直到肿瘤量达50.4～61.2 Gy。结果随访中位时间为24.5个月（2.7～60.3个月）,15例存活2,7例死亡。2年总生存率为42%。31例复发：24例为原位复发5,例为远处转移2,例为局部和远处转移。2年无病生存率为9.2%。3级以上白细胞下降及放射性食管炎发生例数分别为12和6例。结论顺铂加伊立替康同步放疗对局部晚期食管癌患者的疗效较好,毒性小,患者可以耐受。

Analysis of the Effect of Concurrent Irinotecan,Cisplatin and Radiotherapy for Locally Advanced Esophageal Cancer

Objective To evaluate the toxicities,response rates and survival outcomes in patients with locally advanced esophageal cancer treated with concurrent cisplatin,irinotecan and radiotherapy.Methods Patients with locally advanced esophageal cancer were treated by concurrent chemoradiotherapy consisting of cisplatin 30 mg/m2 and irinotecan 65 mg/m2 on days 1 and 8,administered every 21 days for four total cycles.Radiotherapy was delivered on the first day of chemotherapy.Results At mean follow-up of 24.5 months...